

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
27 May 2004 (27.05.2004)

PCT

(10) International Publication Number
WO 2004/043985 A1

(51) International Patent Classification⁷: C07H 17/08, A61K 31/7048

(74) Agent: PLIVA d.d.; PRAVNI POSLOVI-Intelektualno vlasništvo, Povrzenic, Nives, Ulica grada Vukovara 49, HR-10000 Zagreb (HR).

(21) International Application Number:
PCT/HR2003/000058

(22) International Filing Date:
10 November 2003 (10.11.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
P20020885A 11 November 2002 (11.11.2002) HR

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): PLIVA d.d. [HR/HR]; Ulica grada Vukovara 49, H-10000 Zagreb (HR).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): KUJUNDZIC, Nedjeljko [HR/HR]; Slavenskog 4, HR-10000 Zagreb (HR). BUKVIC KRAJACIC, Mirjana [HR/HR]; Tjardoviceva 28, HR-10000 Zagreb (HR). BRAJSA, Karmen [HR/HR]; Jablanska 42, HR-10000 Zagreb (HR).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SUBSTITUTED 9A-N-{N'-[4-(SULFONYL)PHENYL]CARBAMOYL} DERIVATIVES OF 9-DEOXO-9-DI-HYDRO-9A-AZA-9A-HOMOERITHROMYCIN A AND 5-O-DESOSAMINYL-9-DEOXO-9-DI-HYDRO-9A-AZA-9A-HOMOERITHRONOLIDE A



(57) Abstract: The invention relates to substituted 9a-N-{N'-[4-(sulfonyl)phenyl]carbamoyle} derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-O-desosaminy-9-deoxo-9-di-hydro-9a-aza-9a-homoerithronolide A, novel semisynthetic macrolide antibiotics of the azalide series general formula (1), wherein R represents H or cladinose moiety and R1 represents chloro, amino, phenylamino, 2-pyridylamino, 3,4-dimethyl-4-isoxazolylamino and 5-methyl-3-isoxazolylamino group, and pharmaceutically acceptable addition salts thereof with inorganic or organic acids, to the process for their preparation of pharmaceutical composition as well as the use their compositions for sterilization rooms and medical instruments as well as for protection of wall and wooden coatings.


Substituted 9a-N-{N'-[4-(sulfonyl)phenylcarbamoyl]} derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A

5 Technical Field

Int. Cl. C07H17/08, A61K31/71

Technical problem

10 The present invention relates to substituted 9a-N-{N'-[4-(sulfonyl)phenylcarbamoyl]} derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A, novel semisynthetic macrolide antibiotics of the azalide series having antibacterial activity of the general formula 1



1

20

wherein R represents H or cladinოსyl moiety, and R¹ represents chloro, amino, phenylamino, 2-pyridylamino, 3,4-dimethyl-5-isoxazolylamino and 5-methyl-3-isoxazolylamino group, to pharmaceutically acceptable addition salts thereof with

25 inorganic or organic acids, to a process for the preparation of the pharmaceutical compositions as well as to the use of pharmaceutical compositions obtained in the treatment of bacterial infections.

Prior Art

30 Erithromycin A is a macrolide antibiotic, whose structure is characterized by 14-membered macrolactone ring having carbonyl group in C-9 position. It was found by McGuire in 1952 [*Antibiot. Chemother.*, 2 (1952) 281] and for over 50 years it has been considered as a reliable and effective antimicrobial agent in the treatment of diseases caused by Gram-positive and some Gram-negative microorganisms. However, in an acidic medium it is easily converted into anhydroerythromycin A, an inactive C-6/C-12 metabolite of a spiroketal structure [P. Kurath et al., *Experientia* 27 (1971) 362]. It is well-known that spirocyclisation of aglycone ring of erythromycin A is successfully inhibited by a chemical transformation of C-9 ketones or hydroxy groups in C-6 and/or C-12 position. By the oximation of C-9 ketones [S. Đokić et al., *Tetrahedron Lett.* 1967: 1945] and by subsequently modifying the obtained 9(E)-oxime into 9-[O-(2-methoxyethoxy)methyloxime] erythromycin A (ROXITHROMYCIN) [G. S. Ambrieres, Fr. Pat. 2,473,525, 1981] or 9(S)-erythromycylamine [R. S. Egan et al., *J. Org. Chem.* 39 (1974) 2492] or a more complex oxazine derivative thereof, 9-deoxy-11-deoxy-9,11-{imino[2-(2-methoxyethoxyethylidene)-oxy]-9(S)-erythromycin A (DIRITHROMYCIN) [P. Lugar i sur., *J. Crist. Mol. Struct.* 9 (1979) 329], novel semisynthetic macrolides were synthesised, whose basic characteristic, in addition to a greater stability in an acidic medium, is a better pharmacokinetics and a long half-time with regard to the parent antibiotic erythromycin A. In a third way for modifying C-9 ketones use is made of Beckmann rearrangement of 9(E)-oxime and of a reduction of the obtained imino ether (G. Kobrehel i sur., U.S. Pat. 4,328,334, 1982.) into 11-aza-10-deoxy-10-dihydroerythromycin A (9-deoxy-9a-aza-9a-homoerythromycin A) under broadening the 14-member ketolactone ring into a 15-member azalactone ring. By reductive N-methylation of 9a-amino group according to Eschweiler-Clark process (G. Kobrehel et al., BE Pat. 892,397, 1982.) or by a preliminary protection of amino group by means of conversion into the corresponding N-oxides and then by alkylation and

55

reduction [G. M. Bright et al., U.S. Pat., 4,474,768, 1984.] N-methyl-11-aza-10-deoxo-10-dihydroerythromycin A (9-deoxo-9a-methyl-9a-aza-9a-homoerithromycin A, AZITHROMYCIN) was synthesized, a prototype of azalide antibiotics, which, in addition to a broad antimicrobial spectrum including Gram-negative bacteria and intracellular microorganisms, are characterized by a specific mechanism of transport to the application site, a long biological half-time and a short therapy period. In EP A 0316128 (G. M. Bright et al.) novel 9a-allyl and 9a-propargyl derivatives of 9-deoxo-9a-aza-9a-homoerythromycin A are disclosed and in U.S. Pat. 4,492,688, 1/1985 (Bright G. M.) the synthesis and the antibacterial activity of the corresponding cyclic ethers are disclosed. In the J. Antibiotics 46 (1993) 1239 (G. Kobrehel et al.) there are further disclosed the synthesis and the activity spectrum of novel 9-deoxo-9a-aza-11-deoxy-9a-homoerythromycin A 9a,11-cyclic carbamates and O-methyl derivatives thereof.

According to the known and established Prior Art, 9a-N-{N'-[4-(sulfonyl)phenyl]carbonyl}] derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A and pharmaceutically acceptable addition salts thereof with inorganic or organic acids, a process for the preparation thereof as well as the preparation methods and use a pharmaceutical preparations have not been disclosed as yet.

It has been found and it is object of the present invention that substituted 9a-N-{N'-[4-(sulfonyl)phenyl]carbonyl}] derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A, novel semisynthetic macrolide antibiotics of the azalide series and pharmaceutically acceptable addition salts thereof with inorganic or organic acids may be prepared by reacting ammonia or substituted amine with 9a-N-{N'-[4-sulfonylphenyl]carbonyl}] derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A which are obtained by reacting of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A with 4-(chlorosulfonyl)phenylisocyanate and optionally by reacting the obtained 9a-N-{N'-[4-(sulfonyl)phenyl]carbonyl}]


derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-O-desosaminyll-
-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A with inorganic and organic acids.

90

Technical Solution

It has been found that novel substituted 9a-N-{N'-[4-(sulfonyl)phenylcarbamoyl]}
derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-O-desosaminyll-
-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A of the general formula 1, wherein R
represents H or cladinosyl group and R¹ represents chloro group,

95




100

1


may be prepared by reacting 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-
-O-desosaminyll-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A of the general
formula 2,

105



2

wherein R represents H or cladinosyl group, with 4-(chlorosulfonyl)phenylisocyanate
 110 formula 3,



3

after that the compounds of general formula 1 were obtained, in which R has previous
 115 meaning, and R¹ represents Cl, by reaction of the compounds general formula 1
 respectively, wherein R represents H or cladinosyl group and R¹ represents Cl, with
 ammonia or substituted amins general formula 4, wherein R² represents H, phenyl
 group, 2-pyridyl group, 3,4-dimethyl-5-isoxazolyl group or 5-methyl-3-isoxazolyl
 group,



4

in toluene, xylene or some other aprotic solvent, at a temperature of 0°C to 110°C.

Pharmaceutically acceptable acid addition salts which also represents an object of the
 present invention, were obtained by reaction of substituted 9a-N-{N'-[4-
 125 -(sulfonyl)phenylcarbamoyl]} derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithro-
 mycin A and 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A with
 an at least equimolar amount of the corresponding inorganic or organic acid such as
 hydrochloric acid, hydroiodic acid, sulfuric acid, phosphoric acid, acetic acid,
 trifluoroacetic acid, propionic acid, benzoic acid, benzene sulfonic acid, methane sulfonic

130 acid, lauryl sulfonic acid, stearic acid, palmitic acid, succinic acid, ethylsuccinic acid, lactobionic acid, oxalic acid, salicylic acid and similar acids, in a solvent inert to the reaction. Addition salts are isolated by evaporating the solvent or, alternatively, by filtration after a spontaneous precipitation or a precipitation by the addition of a non-polar cosolvent.

135 Substituted 9a-N-{N'-[4-(sulfonyl)phenyl]carbamoyl} derivatives of 9-deoxy-9-dihydro-9a-aza-9a-homoerithromycin A and 5-O-desosaminyl-9-deoxy-9-dihydro-9a-aza-9a-homoerithronolide A of the general formula 1 and pharmaceutically acceptable addition salts with inorganic or organic acids thereof possess an antibacterial activity *in vitro*.

140 Minimal inhibitory concentration (MIC) is defined as the concentration which shows 90% growth inhibition, and was determined by broth dilution methods according to National Committee for Clinical Laboratory Standards (NCCLS, M7-A2) protocols. Final concentration of test substances were in range from 64 to 0.125 µg/ml. MIC levels for all compounds were determined on panel of susceptible and resistant Gram positive bacterial strains (*S. aureus*, *S. pneumoniae* and *S. pyogenes*) and on Gram negative strains (*E. coli*, *H. influenzae*, *E. faecalis*, *M. catarrhalis*).

145 Test substances from Example 3 to 7 were active on susceptible strains of *S. pyogenes* (MIC 2 to 8 µg/ml), and on susceptible strains of *S. pneumoniae* (MIC 0.5 to 8 µg/ml).
150 Substances from Example 3 and 4 showed strong antimicrobial activities on *S. pyogenes* iMLS resistant strain (MIC 2 µg/ml).

The obtained results for substances from Example 3 to 7 expressed as MIC in mg/ml suggest a potential use thereof as sterilization agents of e.g. rooms and medical instruments and as industrial microbial agents e. g. for the protection of wall and
155 wooden coatings.

Process for the preparation of 9a-N-{N'-[4-(sulfonyl)phenyl]carbamoyl} derivatives of 9-deoxy-9-dihydro-9a-aza-9a-homoerithromycin A and 5-O-desosaminyl-9-deoxy-9-dihydro-9a-aza-9a-homoerithronolide A of this invention is illustrated by the following
160 Examples which should in no way be construed as a limitation of the scope thereof.

Example 1

9-Deoxo-9-dihydro-9a-N-{[4-(chlorosulfonyl)phenyl]carbamoyl}-9a-aza-9a-
-homoerithromycin A

A mixture of 1.35 g (1.84 mmol) 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 0.40 (1.84 mmol) 4-(chlorosulfonyl)phenylisocyanate and 30 ml dry toluene was stirred 1 hour at the temperature 0°-5°C. The reaction mixture was evaporated at reduced pressure to dryness to give crude 9-deoxo-9-dihydro-9a-N-{[4-(chlorosulfonyl)phenyl]carbamoyl}-9a-aza-9a-homoerithromycin A. The pure product was obtained, where from by chromatography the crude product on a silica gel column using solvent methylene chloride.

MS(ES⁺) m/z = 794.

Example 2

5-O-Desosaminyl-9-deoxo-9-dihydro-9a-N-{[4-(chlorosulfonyl)phenyl]carbamoyl}-9a-
-aza-9a-homoerithronolide A

Analogously to the process disclosed in Example 1, from 1.95 g (2.0 mmol) 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A and 0.43 g (2.0 mmol) 4-(chlorosulfonyl)phenylisocyanate in 30 ml dry toluene crude product was obtained, wherefrom by chromatography on silica gel column using methylene chloride as a solvent. Pure 5-O-desosaminyl-9-deoxo-9-dihydro-9a-N-{[4-(chlorosulfonyl)phenyl]carbamoyl}-9a-aza-9a-homoerithronolide A was obtained.

MS (ES⁺)m/z = 794.

Example 3

9-Deoxo-9-dihydro-9a-N-{[4-(aminosulfonyl)phenyl]carbamoyl}-9a-aza-9a-
-homoerithromycin A

The solution of 1.35 g (1.84 mmol) 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 0.4 g (1.84 mmol) 4-(chlorosulfonyl)phenyl isocyanate in 30 ml dry toluene was

195 stirred about 1.0 hour at the temperature 0°- 5°C. In the reaction mixture 5.0 ml (4.55 g;
61.5 mmol) 23 % water solution of ammonia was added and the reaction mixture was
stirred about 30 minutes at room temperature. The crude product was filtered,
wherefrom by column chromatography on silica gel using solvent system methylen-
chloride : methanol = 9 : 1. Pure 9-deoxo-9-dihydro-9a-N-{[4-(aminosulfonyl)phenyl]-
carbamoyl}-9a-aza-9a-homoerithromycin A was obtained.

200 IR (KBr)/cm⁻¹ = 1727, 1638, 1593, 1552, 1126, 1013.

¹H NMR (500 MHz; CDCl₃/δ) = 4.41 (1H, H-1'), 4.76 (1H, H-1''), 4.00 (1H, H-3),
3.41 (1H, H-5), 3.20 (3H, 3''-OCH₃), 2.89 (1H, 4''), 2.50 (6H, 3'-N'(CH₃)₂), 2.26
(1H, H-2''a), 1.51 (1H, H-2''b), 1.29 (1H, H-8), 0.96 (3H, 10-CH₃), 0.89 (3H 4-CH₃),
205 0.80 (3H, H-15).

¹³C NMR (500 MHz; CDCl₃/δ) = 175.6 (C-1), 155.5 (9a-N_CCONH), 101.9 (C-1'),
95.2 (C-1''), 84.1 (C-5), 78.3 (C-3), 48.8 (3''-OCH₃), 44.5 (C-2), 27.6 (C-8), 19.9 (8-
CH₃), 9.2 (10-CH₃), 11.1 (C-15).

210 MS (ES⁺) m/z (%) = 933.

Example 4

215 9-Deoxo-9-dihydro-9a-N-{N'-[4-(phenylaminosulfonyl)phenyl]carbamoyl}-9a-aza-9a-
-homoerithromycin A

Analogously to the process disclosed in Example 3, from 1,35 g (1,84 mmol) 9-deoxo-
-9-dihydro-9a-aza-9a-homoerithromycin A, and 0,4 g (1,84 mmol) 4-
-(chlorosulfonyl)phenyl isocyanate, 1,0 ml (11,0 mmol) aniline in 30 ml dry toluene 0,8
220 g pure 9-deoxo-9-dihydro-9a-N-{N'-[4-(aminosulfonyl)phenyl]carbamoyl}-9a-aza-9a-
-homoerithromycin A was obtained with following spectral data.

IR (KBr)/cm⁻¹ = 1727, 1638, 1593, 1552, 1126, 1013.

225 ^1H NMR (500 MHz; CDCl_3/δ) = 4.45 (1H, H-1'), 4.76 (1H, H-1''), 4.01 (1H, H-3), 3.38 (1H, H-5), 3.22 (3H, 3''-OCH₃), 2.90 (1H, 4''), 2.50 (6H, 3'-N'(CH₃)₂), 2.26 (1H, H-2''a), 1.52 (1H, H-2''b), 1.27 (1H, H-8), 0.90 (3H, 10-CH₃), 0.89 (3H 4-CH₃), 0.79 (3H, H-15).

230 ^{13}C NMR (500 MHz; CDCl_3/δ) = 179.0 (C-1), 155 (9a-N $\underline{\text{C}}$ ONH), 103.8 (C-1'), 95.8 (C-1''), 84.7(C-5), 79.0 (C-3), 50.0 (3''-OCH₃), 46.5 (C-2), 27.9 (C-8), 20.4 (8-CH₃), 9.2 (10-CH₃), 11.3 (C-15).

MS (ES^+) m/z (%) = 1009.

235

Example 5

9-Deoxo-9-dihydro-9a-N-{N'-[4-(2-pyridylaminosulfonyl)phenyl]carbamoyl}-9a-aza-9a-homoerithromycin A

240 Analogously to the process disclosed in Example 3, from 1.35 g (1.84 mmol) 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A, 0.4 g (1.84 mmol) 4-(chlorosulfonyl)phenyl isocyanate and 0.70 g (5.2 mmol) 2-aminopyridine in 30 ml dry toluene 0.5 g pure 9-deoxo-9-dihydro-9a-N-{N'-[4-(2-pyridylaminosulfonyl)phenyl]carbamoyl}-9a-aza-9a-homoerithromycin A was obtained with following spectral data.

245

IR (KBr)/ cm^{-1} = 1727, 1638, 1593, 1552, 1126, 1013.

^1H NMR (500 MHz; CDCl_3/δ) = 4.41 (1H, H-1'), 4.75 (1H, H-1''), 4.00 (1H, H-3), 3.38 (1H, H-5), 3.21 (3H, 3''-OCH₃), 2.89 (1H, 4''), 2.50 (6H, 3'-N'(CH₃)₂), 2.27 (1H, H-2''a), 1.48 (1H, H-2''b), 1.27 (1H, H-8), 0.89 (3H, 10-CH₃), 0.88 (3H 4-CH₃), 0.79 (3H, H-15).

250

^{13}C NMR (500 MHz; CDCl_3/δ) = 175.6 (C-1), 155.4 (9a-N $\underline{\text{C}}$ ONH), 101.9 (C-1'), 95.1 (C-1''), 84.0 (C-5), 78.1 (C-3), 48.8 (3''-OCH₃), 46.5 (C-2), 27.6 (C-8), 19.9 (8-CH₃), 9.1 (10-CH₃), 11.1 (C-15).

255

MS (ES^+) m/z (%) = 1014.

260

Example 6

9-Deoxo-9-dihydro-9a-N-{N'-[4-(3,4-dimethyl-5-isoxazolylaminosulfonyl)phenyl]-carbamoyl}-9a-aza-9a-homoerithromycin A

265

Analogously to the process disclosed in Example 3, from 1.35 g (1.84 mmol) 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A, 0.4 g (1.84 mmol) 4-(chlorosulfonyl)phenyl isocyanate and 0.41 g (3.67 mmol) 5-amino-3,4-dimethylisoxazole in 30 ml dry toluene 1.5 g pure 9-deoxo-9-dihydro-9a-N-{N'-[4-(3,4-dimethyl-5-isoxazolylaminosulfonyl)-phenyl]carbamoyl}-9a-aza-9a-homoerithromycin A was obtained.

270

MS (ES⁺) m/z (%) = 1028.

Example 7

9-Deoxo-9-dihydro-9a-N-{N'-[4-(5-methyl-3-isoxazolylaminosulfonyl)phenyl]-carbamoyl}-9a-aza-9a-homoerithromycin A

275

Analogously to the process disclosed in Example 3, from 1.35 g (1.84 mmol) 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A, 0.4 g (1.84 mmol) 4-(chlorosulfonyl)phenyl isocyanate and 0.36 g (3.67 mmol) 3-amino-5-methylisoxazole in 30 ml dry toluene 0.40 g pure 9-deoxo-9-dihydro-9a-N-{N'-[4-(5-methyl-3-isoxazolylaminosulfonyl)-phenyl]carbamoyl}-9a-aza-9a-homoerithromycin A was obtained with following spectral data.

280

¹H NMR (500 MHz; CDCl₃/δ) = 4.42 (1H, H-1'), 4.75 (1H, H-1''), 4.01 (1H, H-3), 3.39 (1H, H-5), 3.20 (3H, 3''-OCH₃), 2.89 (1H, 4''), 2.50 (6H, 3'-N'(CH₃)₂), 2.24 (1H, H-2''a), 1.48 (1H, H-2''b), 1.28 (1H, H-8), 0.90 (3H, 10-CH₃), 0.87 (3H 4-CH₃), 0.79 (3H, H-15).

285

¹³C NMR (500 MHz; CDCl₃/δ) = 175.8 (C-1), 155.6 (9a-N $\underline{\text{C}}$ ONH), 101.7 (C-1'),
290 95.8 (C-1''), 84.0 (C-5), 78.3 (C-3), 48.9 (3''-OCH₃), 45 (C-2), 27.8 (C-8), 20.2 (8-
CH₃), 9 (10-CH₃), 11.3 (C-15).

MS (ES⁺) m/z (%) = 1014.

295 Example 8

5-O-Desosaminy-9-deoxo-9-dihydro-9a-N-[4-(aminosulfonylphenyl)carbamoyl]-9a- -aza-9a-homoerithronolide A

Analogously to the process disclosed in Example 3, from 1.15 g (2.0 mmol) 5-O-
300 -desosaminy-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A, 0.43 g (2.0 mmol) 4-
-(chlorosulfonyl)phenyl isocyanate and 5.0 ml (4.55 g; 61.5 mmol) 23 % water solution
of ammonia in 30 ml xylene 0.60 g pure 5-O-desosaminy-9-deoxo-9-dihydro-9a-N-[4-
-(aminosulfonylphenyl)carbamoyl]-9a-aza-9a-homoerithronolide A was obtained with
following spectral data.

305

¹H NMR (500 MHz; piridin/δ) = 8.16, 7.93, 7.93, 7.5 (1H, fenilni), 5.60 (1H, H-13)
5.1 (1H, H-1'), 4.41 (1H, H-5) 4.30 (1H, H-3), 3.61
(1H, H-5'), 3.49 (1H, H-2'), 3.02 (1H, H-2), 2.61 (1H,
H-3'), 2.21 (6H, 3'-N(CH₃)₂), 2.36 (1H, H-14a), 1.70
310 (1H, H-4'a), 1.87 (1H, H-14b), 1.69 (1H, H-4) 1.52
(1H, H-4'b), 1.58 (3H, 2-CH₃), 1.01 (3H, H-15).

¹³C NMR (500 MHz; piridin/δ) = 178 (C-1), 156.7 (NH $\underline{\text{C}}$ ONH), 144.8, (fenil.), 133.2
(fenil.), 131.5, 129.3, 127.6, 115.3, (CH, fenil.), 103.3
315 (C-1'), 75.0 (C-13) 75.4 (C-3), 69.9 (C-5'), 69.2 (C-2')
68.0 (C-5), 65.4 (C-3') 45.6 (C-2), 40.3 (3'-N(CH₃)₂),
39.1 (C-4), 23.2 (C-14), 29.2 (C-4'), 16.7 (2-CH₃), 11.4
(C-15).

MS (ES⁺) m/z (%) = 775.

320

Example 9**5-O-Desosaminy-9-deoxo-9-dihydro-9a-N-{N'-[4-(phenylaminosulfonyl)phenyl]-carbamoyl}-9a-aza-9a-homoerithronolide A**

325 Analogously to the process disclosed in Example 3, from 1.15 g (2.0 mmol) 5-O-
-desosaminy-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A, 0.43 g (2.0 mmol) 4-
-(chlorosulfonyl)phenyl isocyanate and 0.4 ml (0.419 g, 4.4 mmol) aniline in 30 ml dry
toluene 0.70 g pure 5-O-desosaminy-9-deoxo-9-dihydro-9a-N-{N'-[4-(phenylamino-
sulfonyl)phenyl]carbamoyl}-9a-aza-9a-homoerithronolide A was obtained with
330 following spectral data.

^1H NMR (500 MHz; CDCl_3/δ) = 4.35 (1H, H-1'), 3.86 (1H, H-3), 3.57 (1H, H-5'),
3.31 (1H, H-2'), 2.67 (1H, H-2), 2.5 (1H, H-3'), 2.30
(6H, 3'-N(CH₃)₂), 1.96 (1H, H-14a), 1.70 (1H, H-4'a),
335 1.56 (1H, H-14b), 1.30 (1H, H-4'b), 0.93 (3H, H-15).

^{13}C NMR (500 MHz; CDCl_3/δ) = 175.8 (C-1), 105.3 (C-1'), 75.4 (C-3), 69.8 (C-5'),
68.9 (C-2') 64.6 (C-3') 44.7 (C-2), 39.6 (3'-N(CH₃)₂),
20.9 (C-14), 29.8 (C-4'), 10.4 (C-15).

340 MS (ES⁺) m/z (%) = 851.

Example 10**5-O-Desosaminy-9-deoxo-9-dihydro-9a-N-{N'-[4-(2-pyridylaminosulfonyl)phenyl]-carbamoyl}-9a-aza-9a-homoerithronolide A**

345 Analogously to the process disclosed in Example 3, from 1.15 g (2.0 mmol) 5-O-
-desosaminy-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A, 0.43 g (2.0 mmol) 4-
-(chlorosulfonyl)phenyl isocyanate and 0.4 g (4.2 mmol) 2-aminopyridine in 30 ml dry
toluene 0.80 g pure 5-O-desosaminy-9-deoxo-9-dihydro-9a-N-{N'-[4-(2-pyridyl-
aminosulfonyl)phenyl]carbamoyl}-9a-aza-9a-homoerithronolide A was obtained with
350 following spectral data.

¹H NMR (500 MHz; CDCl₃/δ) = 8.30, 7.64 7.38, 7.64 (1H, aminopiridin), 4.34 (1H, H-1'), 3.84 (1H, H-3), 3.58 (1H, H-5'), 3.31 (1H, H-2'), 2.63 (1H, H-2), 2.6 (1H, H-3'), 2.29 (6H, 3'-N(CH₃)₂), 1.94 (1H, H-14a), 1.71 (1H, H-4'a), 1.55 (1H, H-14b), 1.29 (1H, H-4'b), 0.92 (3H, H-15).

¹³C NMR (500 MHz; CDCl₃/δ) = 141.5, 140.8, 114.5, 114.1 (aminopiridin), 105.4 (C-1'), 75.3 (C-3), 69.9 (C-5'), 68.9 (C-2'), 64.6 (C-3'), 44.7 (C-2), 39.6 (3'-N(CH₃)₂), 20.9 (C-14), 29.9 (C-4'), 10.4 (C-15).

MS (ES⁺) m/z (%) = 852.

Example 11

5-O-Desosaminy-9-deoxo-9-dihydro-9a-N-{N'-[4-(3,4-dimethyl-3-isoxazolylaminosulfonyl)phenyl]carbamoyl}-9a-aza-9a-homoerithronolide A

Analogously to the process disclosed in Example 3, from 1.15 g (2.0 mmol) 5-O-desosaminy-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A, 0.43 g (2.0 mmol) 4-(chlorosulfonyl)phenyl isocyanate and 0.45 g (4.0 mmol) 5-amino-3,4-dimethylisoxazole in 30 ml dry toluene 0.75 g pure 5-O-desosaminy-9-deoxo-9-dihydro-9a-N-{N'-[4-(3,4-dimethyl-3-isoxazolylaminosulfonyl)phenyl]carbamoyl}-9a-aza-9a-homoerithronolide A was obtained with following spectral data.

MS (ES⁺) m/z (%) = 870.

Example 12

5-O-Desosaminy-9-deoxo-9-dihydro-9a-N-{N'-[4-(5-methyl-3-isoxazolylaminosulfonyl)phenyl]carbamoyl}-9a-aza-9a-homoerithronolide A

Analogously to the process disclosed in Example 3, from 1.15 g (2.0 mmol) 5-O-desosaminy-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A, 0.43 g (2.0 mmol) 4-(chlorosulfonyl)phenyl isocyanate and 0.39 g (4.0 mmol) 3-amino-5-methylisoxazole in 30 ml dry toluene 0.7 g pure 5-O-desosaminy-9-deoxo-9-dihydro-9a-N-{N'-[4-(5-

385 -methyl-3-isoxazolylaminosulfonyl]phenyl]carbamoyl}-9a-aza-9a-homoerithronolide A
was obtained with following spectral data.

390 ^1H NMR (500 MHz; CDCl_3/δ) = 4.36 (1H, H-1'), 3.87 (1H, H-3), 3.56 (1H, H-5'),
3.32 (1H, H-2'), 2.65 (1H, H-2), 2.48 (1H, H-3'), 2.32
(6H, 3'-N(CH₃)₂), 1.95 (1H, H-14a), 1.70 (1H, H-4'a),
1.55 (1H, H-14b), 1.30 (1H, H-4'b), 0.90 (3H, H-15).


^{13}C NMR (500 MHz; CDCl_3/δ) = 105.6 (C-1'), 74.6 (C-3), 69 (C-5'), 69.3 (C-2') 64.6
(C-3') 44 (C-2), 40.1 (3'-N(CH₃)₂), 21.4 (C-14), 30.2
(C-4'), 10.8 (C-15).

395

MS (ES^+) m/z (%) = 856.

CLAIMS

- 400 1. Substituted 9a-N-{N'-[4-(sulfonyl)phenyl]carbamoyl}} derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-O-desosamynil-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A of the general formula 1,



1

405


wherein R represents H or cladinosyl moiety, and R¹ represents chloro, amino, phenylamino, 2-pyridylamino, 3,4-dimethyl-5-isoxazolylamino and 5-methyl-3-isoxazolylamino group, and pharmaceutically acceptable addition salts thereof with inorganic or organic acids.

410

2. A substance according to claim 1, characterized in that R¹ represents chloro group and R represents cladinosyl moiety.
3. A substance according to claim 1 characterized in that R¹ represents chloro group, and R represents H.
4. Substance according to claim 1 where R¹ represents amino group, and R represents cladinosyl moiety.
5. A substance according to claim 1, characterized in that R¹ represents phenylamino group, and R represents cladinosyl group.
6. A substance according to claim 1, characterized in that R¹ represents 2-pyridylamino group, and R represents cladinosyl group.

415


- 420 7. A substance according to claim 1, characterized in that R^1 represents 3,4-dimethyl-5-isoxazolyl group, and R represents cladinosyl moiety.
8. A substance according to claim 1, characterized in that R^1 represents 5-methyl-3-isoxazolylamino group, and R represents cladinosyl group.
9. A substance according to claim 1, characterized in that R^1 represents amino group and R represents H.
- 425 10. A substance according to claim 1, characterized in that R^1 represents phenylamino group, and R represents H.
11. A substance according to claim 1, characterized in that R^1 represents 2-pyridylamino group, and R represents H.
- 430 12. A substance according to claim 1, characterized in that R^1 represents 3,4-dimethyl-5-isoxazolylamino group, and R represents H.
13. A substance according to claim 1, characterized in that R^1 represents 5-methyl-3-isoxazolylamino group and R represents H.
- 435 14. A process for the preparation of substituted 9a-N-{N'-[4-(sulfonyl)phenyl]carbamoyl}} derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A of the general formula 1,



1

- 440 wherein R^1 represents chloro, amino, phenylamino, 2-pyridylamnio, 3,4-dimethyl-5-isoxazolylamino and 5-methyl-3-isoxazolylamino group and R represents H or cladinosyl group, characterized in that 9a-N-{N'-[4-(chlorosulfonyl)phenyl]-


carbamoyl} derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-O-desosaminy-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A general formula 1, wherein R¹ represents chloro group and R represent H or cladinosyl group, which
 445 can be prepared by reaction of 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A or 5-O-desosaminy-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A general formula 2



450

2


wherein R represents H or cladinosyl group with 4-(chlorosulfonyl)phenyl isocyanate
 formula 3,



3

455

are subjected to a reaction with ammonia or amine of general formula 4,



4

460

wherein R² represents H or phenyl, 2-pyridyl, 3,4-dimethyl-5-isoxazolyl or 5-methyl-3-isoxazolyl group, in toluene, xylene or some other aprotic solvent, at a
 temperature 0-110°C and then, if appropriate, to a reaction with inorganic or
 organic acids.

15. Pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antibacterially effective amount of the substances according to claim 1.

- 465 16. A use of a substance of according to any claims 1-13 for preparing compositions for sterilization rooms and medical instruments as well as for protection of wall and wooden coatings.

INTERNATIONAL SEARCH REPORT

International Application No
PC1/HR 03/00058

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07H17/08 A61K31/7048

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07H A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

CHEM ABS Data, EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 00 66603 A (MARU & SCARON ;MUTAK STJEPAN (HR); KUJUND & ZCARON (HR); MAR & SCA) 9 November 2000 (2000-11-09) the whole document	
A	EP 0 657 464 A (PLIVA PHARM & CHEM WORKS) 14 June 1995 (1995-06-14) the whole document	
A	KUJUNDZIC, N. ET AL: "Azalides: synthesis and antibacterial activity of novel 9a-(N'-substitute carbamoyl and thiocarbamoyl) derivatives of 9-deoxo-9a-aza-9a- homoerythromycin A" EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (1995), 30(6), 455-62 , 1995, XP004040166 the whole document	

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

24 February 2004

Date of mailing of the international search report

03/03/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Klein, D

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/HR 03/00058

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0066603	A	09-11-2000	HR 990130 A1 31-10-2001
			AT 244258 T 15-07-2003
			AU 767681 B2 20-11-2003
			AU 4135000 A 17-11-2000
			BG 106173 A 31-07-2002
			BR 0010231 A 19-02-2002
			CA 2372977 A1 09-11-2000
			CN 1351606 T 29-05-2002
			CZ 20013913 A3 17-04-2002
			DE 60003671 D1 07-08-2003
			DK 1175429 T3 20-10-2003
			EE 200100582 A 17-02-2003
			EP 1175429 A1 30-01-2002
			WO 0066603 A1 09-11-2000
			HU 0201146 A2 29-07-2002
			JP 2002543213 T 17-12-2002
			NO 20015346 A 01-11-2001
			NZ 515278 A 30-06-2003
			PL 351402 A1 07-04-2003
			PT 1175429 T 28-11-2003
			SI 1175429 T1 31-12-2003
			SK 15702001 A3 04-04-2002
			TR 200103143 T2 22-04-2002
			ZA 200108484 A 16-01-2003
EP 0657464	A	14-06-1995	HR 931480 A1 31-08-1996
			AT 144778 T 15-11-1996
			BG 61571 B1 30-12-1997
			BG 99242 A 29-09-1995
			CA 2137395 A1 09-06-1995
			CN 1109890 A ,B 11-10-1995
			CZ 9403082 A3 12-07-1995
			DE 69400817 D1 05-12-1996
			DE 69400817 T2 22-05-1997
			EP 0657464 A1 14-06-1995
			ES 2096401 T3 01-03-1997
			HU 69283 A2 28-09-1995
			JP 3131546 B2 05-02-2001
			JP 7252292 A 03-10-1995
			PL 306154 A1 12-06-1995
			RO 113854 B1 30-11-1998
			RU 2131878 C1 20-06-1999
			SI 9400434 A 30-06-1995
			SK 146994 A3 11-07-1995
			US 5629296 A 13-05-1997